Rhumbline Advisers Humacyte, Inc. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Humacyte, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 177,623 shares of HUMA stock, worth $291,301. This represents 0.0% of its overall portfolio holdings.

Number of Shares

177,623

Previous 117,564 51.09%

Holding current value

$291,301

Previous $201,000 84.58%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$1.15 - $2.77 $69,067 - $166,363	60,059 Added 51.09%	177,623 $371,000
Q1 2025 Apr 08, 2025	BUY	$1.71 - $5.18 $5,316 - $16,104	3,109 Added 2.72%	117,564 $230,000
Q4 2024 May 29, 2025	SELL	$3.46 - $5.81 $10,757 - $18,063	-3,109 Reduced 2.64%	114,455 $577,000
Q4 2024 Jan 30, 2025	BUY	$3.46 - $5.81 $17,317 - $29,079	5,005 Added 4.57%	114,455 $577,000
Q3 2024 Nov 12, 2024	SELL	$5.11 - $9.46 $7,506 - $13,896	-1,469 Reduced 1.32%	109,450 $595,000
Q2 2024 Aug 01, 2024	BUY	$2.87 - $9.1 $148,832 - $471,907	51,858 Added 87.8%	110,919 $532,000
Q1 2024 May 09, 2024	BUY	$2.57 - $4.84 $5,618 - $10,580	2,186 Added 3.84%	59,061 $183,000
Q4 2023 Feb 08, 2024	BUY	$1.99 - $3.12 $3,840 - $6,021	1,930 Added 3.51%	56,875 $161,000
Q3 2023 Nov 09, 2023	BUY	$2.75 - $4.48 $3,940 - $6,419	1,433 Added 2.68%	54,945 $160,000
Q2 2023 Aug 08, 2023	BUY	$2.86 - $4.97 $12,584 - $21,868	4,400 Added 8.96%	53,512 $153,000
Q1 2023 May 11, 2023	SELL	$2.11 - $3.25 $4,629 - $7,130	-2,194 Reduced 4.28%	49,112 $152,000
Q4 2022 Feb 14, 2023	BUY	$2.02 - $3.62 $57,614 - $103,249	28,522 Added 125.18%	51,306 $108,000
Q3 2022 Nov 10, 2022	BUY	$1.22 - $5.14 $1,651 - $6,959	1,354 Added 6.32%	22,784 $74,000
Q2 2022 Aug 11, 2022	BUY	$3.21 - $7.86 $68,790 - $168,439	21,430 New	21,430 $69,000

Others Institutions Holding HUMA

# of Institutions

170

Shares Held

54.4M

Call Options Held

1.1M

Put Options Held

808K

View Full List

About Humacyte, Inc.

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $169M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

More about HUMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Humacyte, Inc. Transaction History